

RECEIVED

MAR 7 2002

TECH CENTER 1600/2900

JENKINS & WILSON, P.A.

PATENT ATTORNEYS
SUITE 1400 UNIVERSITY TOWER
3100 TOWER BOULEVARD
DURHAM, NORTH CAROLINA 27707

TELEPHONE (919) 493-8000
FACSIMILE (919) 419-0383

WEBSITE
JENKINSANDWILSON.COM

RALEIGH OFFICE

NCSU CENTENNIAL CAMPUS
VENTURE II SUITE 400
920 MAIN CAMPUS DRIVE
RALEIGH, NORTH CAROLINA 27606

TELEPHONE (919) 424-3710
FACSIMILE (919) 424-3711

RICHARD E. JENKINS
JEFFREY L. WILSON
ARLES A. TAYLOR, JR.
DAVID P. GLOEKLER
GREGORY A. HUNT
JOHN A. LAMERDIN, PH.D.
E. ERIC MILLS
JULIE A. BROADUS, Ph.D. (PATENT AGENT)
OF COUNSEL:
JENNIFER L. SKORD

RECEIVED

December 12, 2001

MAR 7 2002

TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. on 12/12/01

Amy J. Martin
Date of Signature 12/12/01

Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Patent Application Serial No. 09/914,605 for X-RAY GUIDED DRUG
DELIVERY
Our File No. 1242/21 PCT/US

Sir:

Please find enclosed in connection with the subject U.S. patent application the following documents:

1. Information Disclosure Statement (2 pages);
2. Forms PTO/SB/08A and PTO/SB/08B (in duplicate);
3. Copies of cited references (14 references); and
4. A return-receipt postcard to be returned to us with the U.S. Patent and Trademark Office filing stamp thereon.

Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any deficiencies of payment associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS & WILSON, P.A.

Arles A. Taylor, Jr.
Registration No. 39,395
Customer No. Bar Code Label:

AAT/ajm

Enclosures



25297

PATENT TRADEMARK OFFICE

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20531 on 12/12/01

Amy J. Martin
Date of Signature 12/12/01



MAR - 7 2002

TECH CENTER 1600/2900
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE #6

In re Application of: Hallahan

Confirmation No.: Not Assigned

Serial No.: 09/914,605

Group Art Unit: Not Assigned

Filed: August 30, 2001

Docket No.: 1242/21 PCT/US

For: X-RAY GUIDED DRUG DELIVERY

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the following references. Forms PTO/SB/08A and PTO/SB/08B are attached hereto. Copies of the references are also enclosed. This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

U.S. Patent No. 4,515,165 to Carroll discloses an apparatus and method for detecting tumors.

U.S. Patent No. 4,670,386 to Sugaar discloses cancer tests using tumor antigen generated lymphokines and compositions.

U.S. Patent No. 5,292,524 to Male et al. discloses a blood platelet loaded with diagnostic or therapeutic-containing liposome or reconstituted sendai virus.

U.S. Patent No. 5,328,840 to Coller discloses a method for preparing targeted carrier erythrocytes.

U.S. Patent No. 5,334,369 to Halushka et al. discloses platelet receptor antagonists useful in detecting intravascular platelet aggregation.

U.S. Patent No. 5,382,680 to Abraham et al. discloses allosteric hemoglobin modifier compounds.

U.S. Patent No. 5,516,881 to Lee et al. discloses aminoxyl-containing radical spin labeling in polymers and copolymers.

U.S. Patent No. 5,693,627 to Schieven discloses the use of phpsphotyrosine phosphatase inhibitors for controlling cellular proliferation.

U.S. Patent No. 5,759,542 to Gurewich discloses compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases.

PCT International Publication No. WO 93/14791 to Cryopharm Corporation discloses a method of inactivation of viral and bacterial blood contaminants.

Publication by Hirata et al., "Artificial Metastases and Decrease of Fibrinolysis in the Nude Mouse Lung After Hemithoracic Irradiation," *Clin. Expl. Metastasis*, Vol. 2 (No. 4), p. 311-319, (1984).

Publication by Hirata, "Fate of Intravenously Injected Human Tumor Cells in the Lung of Nude Mice Following Whole-Body X-Irradiation," *Invasion Metastasis*, p. 61-70, (1985).

Publication by Stratton et al., "Imaging Arterial Thrombosis: Comparison of Technetium-99m-Labeled Monoclonal Antifibrin Antibodies and Indium-111-Platelets," *J. Nucl. Med.*, p. 1731-1737, (1994).

Publication by Weichselbaum et al., "Gene Therapy Targeted by Radiation Preferentially Radiosensitizes Tumor Cells," *Cancer Research*, p. 4266-4269, (August 15, 1994).

Early passage of the subject application to issue is earnestly solicited.

Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any deficiencies of payment associated with the filing of this Information Disclosure Statement to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS & WILSON, P.A.

Date: 12/12/01

By:

Arles A. Taylor, Jr.
Arles A. Taylor, Jr.
Registration No. 39,395

Suite 1400 University Tower
3100 Tower Boulevard
Durham, North Carolina 27707
Telephone: (919) 493-8000
Facsimile: (919) 419-0383

Customer No. Bar Code Label:



1242/21 PCT/US AAT/ajm

25297

PATENT TRADEMARK OFFICE

Enclosures

JAN 07 2002

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/914.605
		Filing Date	08/30/2001
		First Named Inventor	Dennis E. Hallahan
		Art Unit	
		Examiner Name	
Sheet 1 of 1	Attorney Docket Number	1242/21 PCT/US	

RECEIVED
MAR 7 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	A1	US- 4,515,165	05/07/1985	Carroll	
	A2	US- 4,670,386	06/02/1987	Sugaar	
	A3	US- 5,292,524	03/08/1994	Male et al.	
	A4	US- 5,328,840	07/12/1994	Coller	
	A5	US- 5,334,369	08/02/1994	Halushka et al.	
	A6	US- 5,382,680	01/17/1995	Abraham et al.	
	A7	US- 5,516,881	05/14/1996	Lee et al.	
	A8	US- 5,693,627	12/02/1997	Schieven	
	A9	US- 5,759,542	06/02/1998	Gurewich	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			


FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)			
	B1	WO 93/14791		Cryopharm Corp.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED
MAR 7 2002
TECH CENTER
1600.2900

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/914.605
Filing Date	08/30/2001
First Named Inventor	Dennis E. Hallahan
Group Art Unit	
Examiner Name	
Attorney Docket Number	1242/21 PCT/US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	HIRATA ET AL., "Artificial Metastases and Decrease of Fibrinolysis in the Nude Mouse Lung After Hemithoracic Irradiation," Clin. Expl. Metastasis, Vol. 2 (No. 4), p. 311-319, (1984).	X
	C2	HIRATA, "Fate of Intravenously Injected Human Tumor Cells in the Lung of Nude Mice Following Whole-Body X-Irradiation," Invasion Metastasis, p. 61-70, (1985).	X
	C3	STRATTON ET AL., "Imaging Arterial Thrombosis: Comparison of Technetium-99m-Labeled Monoclonal Antifibrin Antibodies and Indium-111-Platelets," J. Nucl. Med., p. 1731-1737, (1994).	X
	C4	WEICHSELBAUM ET AL., "Gene Therapy Targeted by Radiation Preferentially Radiosensitizes Tumor Cells," Cancer Research, p. 4266-4269, (August 15, 1994).	X

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.